2. Time to complete wound healing.

Study or Subgroup	Antibiotic			Control			P value	Hazard Ratio (HR)
	Mean	SD	N	Mean	SD	N
Neomycin, bacitracin and polymyxin B vs control/placebo
Fisher 1968	22.0	—	33	24.0	—	33	—
Silver sulfadiazine vs polymyxin B/bacitracin
Soroff 1994	15.0	20.3	15	10.0	4.6	15	P value 0.0007
Silver sulfadiazine vs dressings (skin substitute)
Barret 2000	16.1	0.6	10	9.7	0.7	10	P value < 0.001
Bugmann 1998	11.26	6.02	35	7.58	3.12	41	P value < 0.01
Caruso 2006	17.0	—	42	16.0	—	42	P value 0.517
Gerding 1988	21.3	2.3	23	13.7	1.3	27	P value < 0.01
Gerding 1990	15.0	1.2	26	10.6	0.8	30	P value < 0.01
Gong 2009	17.3	4.56	52	13.1	3.5	52	P value < 0.05
Gotschall 1998	27.6	—	30	10.5	—	33	P value 0.0002
Noordenbos 1999	18.1	6.05	14	11.1	4.37	14	P value 0.002
Tayade 2006	18.44	—	25	12.64	—	25	—
Silver sulfadiazine vs any topical preparation of natural products (traditional medicine)
Ang 2001	20.0	—	58	17.0	—	57	P value 0.11	0.67
Khorasani 2009	18.73	2.65	30	15.9	2.0	30	P value < 0.0001
Moharamzad 2010	9.7	3.5	55	12.8	1.8	56	P value < 0.05
Topical antibiotic prophylaxis vs other treatments
Fisher 1968	22.0	—	33	23.0	—	33	—
Hauser 2007	11.3	4.9	47	9.9	4.5	47	P value 0.015
Other topical antibiotics vs dressings (skin substitute)
Demling 1999	13.0	3.5	11	8.0	1.5	10	P value < 0.05
Demling 2003	10.5	—	20	8.5	—	24	P value < 0.05
Non‐absorbable antibiotic prophylaxis vs placebo
Barret 2001	40.0	8.0	11	33.0	4.0	12	—

Abbreviations

< = less than
 vs = versus